Patient profiled data for treatment decision-making: valuable as an add-on to hepatitis C clinical guidelines?

ABSTRACT:

Background and aims

Systematic reviews and medical guidelines are widely used in clinical practice. However, these are often not up-to-date and focussed on the average patient. We therefore aimed to evaluate a guideline add-on, TherapySelector (TS), which is based on monthly updated data of all available high-quality studies, classified in specific patient profiles.

Methods

We evaluated the TS for the treatment of hepatitis C (HCV) in an international cohort of patients treated with direct-acting antivirals between 2015 and 2020. The primary outcome was the number of patients receiving one of the two preferred treatment options of the HCV TS, based on the highest level of evidence, cure rate, absence of ribavirin-associated adverse effects, and treatment duration.

Results

SUBMITTER: Brakenhoff SM 

PROVIDER: S-EPMC11321176 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature